|Bid||349.07 x 900|
|Ask||349.39 x 1400|
|Day's Range||348.53 - 354.07|
|52 Week Range||220.05 - 376.43|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||28.00|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||390.00|
We can judge whether Bio-Rad Laboratories, Inc. (NYSE:BIO) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2019.
Tamarack Capital Management was founded by Justin John Ferayorni, who remained the fund’s Chief Investment Officer and Portfolio Manager. Mr. Ferayorni holds A.B. degree in Chemistry from Princeton University, as well as Chartered Financial Analyst designation. Prior to founding Tamarack Capital Management, he worked as Healthcare Analyst and Portfolio Manager. He also held a position of […]
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2019 on Thursday, October 31, 2019, following the close of the market.
This is now the second time in roughly a year that actress Elizabeth Banks -- and the marketing team at State Street -- has told us to pay attention to the "middle." And yet, most of us continue to ignore her siren call about mid-cap stocks, which is a huge shame because she happens to be right. Mid-cap stocks and ETFs like the SPDR S&P MidCap 400 ETF (NYSEArca:MDY) are darn good for your portfolio.It turns out that mid-cap stocks fall right in the sweet spot for long-term growth. They aren't too big that their best days are behind them. At the same time, they are just big enough to survive economic duress and downturns. Many of the brands and services we use day-to-day are actually performed by mid-cap companies. Add in their higher rates of dividend growth and you have a recipe for long-term success.Just how much success? Mid-cap stocks, roughly defined as companies between $2 billion and $10 billion in market capitalization, have managed to produce an extra 753% cumulative return over small-caps since the 1990s. And they've done so with less overall volatility. Meanwhile, mid-caps have managed to outperform their larger rivals as well over that time period.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Hot Stocks Staging Huge Reversals The reality is, mid-cap stocks offer the perfect blend of growth and stability that many investors need. We should listen to Banks' advice and head towards the middle. Mid-caps really are that great for our portfolio's health. With that, here are five mid-cap stocks that could be great additions to your investments. Mighty Mid-Cap Stocks to Buy: Zebra Technologies (ZBRA)There's a good chance that you've never heard of Zebra Technologies (NASDAQ:ZBRA). But I can guarantee if you've ever been shopping at some point in your life -- either online or in-store -- your purchase has interacted with their products.Source: The DEMO Conference via FlickrZBRA makes all sorts of barcode scanners, printers, RFID labels, software, and other inventory tracking gear. All of their products are a must-have for retailers looking to ship and stock their shelves. And even more so in the world of omnichannel retailing.With consumers wanting their goods when and how they want them, inventory tracking has become even more important. For Zebra, that's meant a surge in sales. Year-over-year, ZBRA managed to see an 8.9% jump in revenues for its latest quarter. This continues a long trend of higher sales. Even better is a shift towards more high-margin software that has helped boost profits by 75% year-over-year.But e-commerce and omnichannel retail sales aren't the only way Zebra is winning. The firm's products are quickly being demanded by hospitals, food producers and other industries as regulations and safety concerns require intense tracking of goods. The addition of IoT products to its mix is also helping. With that, ZBRA has plenty of room to grow over the long haul.With plenty of cash flows, a new $1 billion buyback program and growth on the horizon, ZBRA is a wonderful mid-cap stock to buy today. Paycom (PAYC)Cloud computing, software as a service (SaaS) and other off-site applications have taken the world by storm. And while there are plenty of larger firms dominating the space, there are many mid-cap stocks winning in the cloud. Case in point: Paycom (NASDAQ:PAYC).PAYC is a perfect example of what the cloud is really good for: automating and performing boring tasks for customers. In this case, it's a variety of human resources functions. Through its suite of applications, Paycom allows HR departments to hire, develop, pay and manage benefits for employees. On the flip side, employees can use PAYC's apps to request time off, enroll in retirement plans, fill in timesheets, etc. Often these tasks can be done via smartphone.The key for PAYC, unlike rival Workday (NASDAQ:WDAY), is that the firm has moved down the ladder in terms of client size. We're talking mom-and-pop businesses to medium-sized firms with a couple hundred employees. This focus has allowed Paycom some great retention rates and growth.Last quarter, PAYC realized a big 31% jump in revenues as it continues to hook more customers and move existing ones into other products. And unlike many smaller cloud stocks, Paycom is profitable -- realizing a 37% jump in EPS year-over-year. * 10 Tech Stocks to Buy Now for 2025 With plenty of ways to add growth and additional customers, PAYC is a prime example of how mid-cap stocks can be used to fuel growth in a portfolio. National Retail Properties (NNN)Sure, many malls across the country are dying a slow death. But not all retail real estate is suffering. Just take a look at your local Taco Bell, bank branch, or Jiffy Lube. These free-standing buildings offer a huge opportunity for mid-cap stock investors -- especially when they are owned by National Retail Properties (NYSE:NNN).NNN owns a huge portfolio of these free-standing buildings and centers -- nearly 3045 to be exact. The win for NNN and its shareholders is that these properties fall under the guise of triple-net leased properties. Here, the tenant is responsible for the payment of taxes, maintenance and other fees associated with renting the property. For landlords, the removal of these extra costs results in a much bigger rent check and profit margin per property. And with its size, National Retail has been able to feast on this fact throughout its history. With its better cash flows, the firm has one of the longest streaks of dividend growth -- 29 years straight -- among all REITs. Currently, NNN yields a healthy 3.6%.The future looks bright for NNN. The vast bulk of its tenants include LA Fitness gyms, 7-Eleven, and Wendy's (NYSE:WEN) franchises. We're talking about internet-proof retail operations. This will continue to boost NNN's occupancy rates and keep the cash flowing towards investors. Bio-Rad Laboratories (BIO)During the gold rush, the people who made the most money weren't the miners themselves, but the stores that provided all the picks and shovels. Today's gold rush could be biotech and healthcare researchers. One of the best mid-cap stocks providing the "picks and shovels" happens to be Bio-Rad Laboratories (NYSE:BIO).BIO may not be as well known to investors as rivals Thermo-Fisher (NYSE:TMO) or Illumina (NASDAQ:ILMN), but its products do find their way into a variety of both public and private research labs. This includes everything from instruments costing tens of thousands of dollars to one-time use consumables and reagents. The combination of products, both advanced and basic, has continued to benefit BIO over its history. Last year, sales at the firm rose 5% as more drug and universities plowed some hefty dollars into research.And that fact doesn't show any signs of slowing. Continued life sciences spending is expected to surge over the next few years by an annual rate of 6% as scientists tackle hard to treat illnesses and diseases. * Buy These 7 Mid-Cap Stocks to Make a Profit This will only help boost BIO's strong pace of growth further. Add in recent wins on the margins front and product additions to its digital life sciences/software segments, and you're looking a great mid-cap stock to own for the long haul. Domino's Pizza (DPZ)Is it a pizza joint or the latest tech start-up full of innovation? For Domino's Pizza (NYSE:DPZ), its looking more like the latter than the former. DPZ has transformed itself over the last few years as it has taken tech spending to a whole new level. The restaurant was one of the first in the sector to offer online ordering. Since that day in 2007, DPZ hasn't looked back.These days, Domino's offers a whole suite of digital tools to make ordering its food easier. This builds on its AnyWare technology. AnyWare allows customers to order a pizza from 15 different methods, including their phone, from their car via Ford (NYSE:F) Sync, Google (NASDAQ:GOOG, NASDAQ:GOOGL) Home devices and even Slack (NASDAQ:WORK) while at the office. And it continues to add more capabilities to the platform. Moreover, it has rolled out new apps including a one-click system that purchases a customer's normal pizza order in 10 seconds.As a result, DPZ has seen sales surge with digital ordering now making up roughly two-thirds of its sales.Now rivals are starting to move into DPZ's territory with new online ordering and applications. However, DPZ continues to innovate and first-mover status still has it coming out ahead in the pizza wars.For investors seeking mid-cap stocks, Domino's could be a great "tech" play.At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Hot Stocks Staging Huge Reversals * 7 Under-The-Radar Growth Stocks That Could Benefit New Investors * 5 Excellent High-Yield Dividend Stocks to Buy The post 5 Stocks to Buy in the Mighty Middle appeared first on InvestorPlace.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Compensation experts say the region's labor market is at an inflection point as demand for top tech talent drives salaries ever-higher. Here's what that means for the median paycheck at companies like Netflix, Facebook, Oracle, Intel and Cisco.
Goldman Sachs has a special rating for stocks which it holds in particularly high regard. This is called a ‘Conviction Buy’ rating. The firm’s prized list of Conviction Buy stocks reveals the stock picks that the investment bank's research team expects to outperform. That’s particularly useful for investors looking for fresh investing inspiration in the face of current market volatility. Here we take a closer look at four stocks that have made it to the firm’s list of top stock ideas. Does the rest of the Street have an equally bullish outlook on these names? Interestingly, all of the stocks covered have received only buy ratings from the Street in the last three months. So no hold or sell ratings here. Let’s take a closer look at what’s keeping analysts on-side now… Comcast Corporation Shares in this cable giant are up 37% year-to-date, and analysts believe further growth lies ahead. Ten analysts have published recent buy ratings on Comcast (CMCSA – Get Report), with Goldman Sachs’ Brett Feldman going so far as to double-upgrade CMCSA all the way from Hold to Conviction Buy. Thanks to "healthy fundamentals across its key businesses”, Feldman foresees "strong growth" over the next three years with annual earnings growth of 11%, free cash flow per share of 12% and dividends of 15%. At the same time, five-star Oppenheimer analyst Timothy Horan has just upgraded Comcast from Hold to Buy. Like Feldman, he has a $54 price target, which translates into upside potential of 16%. So what’s the reason behind his bullish transition on the stock? The analyst referred to a triple whammy of broadband strength, underestimated ad revenue, and secular cable improvements. “Fundamentals are healthy in the near-term, and we think 2020 is setting up to be a strong year.” Horan stated. “Cable margins should continue to expand as revenue mix shifts to higher margin broadband (estimated 70% adj. EBITDA margins) vs. video (estimated 20% margins).” Voya Financial IncBased in New York, Voya Financial (VOYA – Get Report) is a retirement, investment and insurance company serving over 13 million customers. On September 12, Goldman Sachs’ Alex Scott upgraded VOYA from Buy to Conviction Buy, citing three key reasons: 1) the possibility of a takeover; 2) potential upside to capital return from life redundant reserve refinancing; and 3) exposure to low interest rates more fully reflected in the valuation. Indeed, the analyst’s Street-high price target of $85 indicates substantial upside potential from current levels of 56%. Note that shares have already surged 35% year-to-date. Meanwhile Morgan Stanley’s Nigel Dally has just met up with Voya management. He left the meetings reassured of his bullish outlook on the company, reiterating his buy rating and $63 price target. The analyst stated "We continue to highlight Voya as one of the most compelling investment opportunities in the life and annuity industry following time on the road through Europe with management. Despite the somewhat disappointing second quarter earnings and lower earnings run-rate, we feel the future prospects for attractive growth and ROE expansion are stronger than what is reflected in the current stock price." Mastercard IncAll eighteen analysts covering Mastercard (MA – Get Report) rate the stock a buy right now. But Goldman Sachs has gone one step further. The firm’s James Schneider has now kept a Conviction Buy rating on Mastercard for over a year. He upgraded the stock to best idea status on September 17 2018, writing at the time that Mastercard is catalyzing the next growth horizon in business-to-business (B2B) payments. "We believe the B2B market represents the next growth horizon for the payments industry and think Mastercard is the best positioned given its multifaceted product approach," Schneider said in a research note. In fact, Goldman Sachs has calculated that B2B payments will represent a whopping $950 billion annualized opportunity for payment stocks. More recently, Schneider reiterated his MA buy rating after management reaffirmed its 2019 guidance. Following the recent earnings call, the analyst told investors that he is optimistic the stock will continue to soar. Shares are already up 46% year-to-date- while the average analyst price target indicates a further 15% upside lies ahead. Bio-Rad Laboratories According to the Street, Bio-Rad (BIO – Get Report) offers attractive exposure to Life Science Tools at a reasonable valuation. With annual sales of $2.2 billion, BIO is among the top five life science companies in the world. And now Goldman Sachs analyst Patrick Donnelly has upgraded Bio-Rad to the Conviction Buy list, citing improving execution and undervalued fundamentals. Looking forward, Donnelly is confident BIO can outperform second half guidance due to strong organic growth, easing comps, margin expansion initiatives, limited maco headwinds and capital deployment. He maintained a $400 price target- indicating 20% upside potential from current levels.In the last three months, only one other analyst has published a rating on BIO stock. That analyst is Barclays’ Jack Meehan. His buy rating comes with a $380 price target- up from $350 previously. “We continue to believe that Bio-Rad has substantial long-term opportunity ahead, and believe there is good visibility into high-teens EPS growth” comments Meehan. He made the call after Bio-Rad delivered solid 2Q19 results, with a notable EPS beat and strong operational discipline. Year-to-date, the stock has rallied 45%. Discover Wall Street’s most loved stocks with the Top Analysts’ Stocks tool
Biome's working capital fell 37% to CA$1,324,582 in the second quarter. Biome's first licensed producer under Canada's Cannabis Act, Highland Grow, reported standalone net profitability in its second commercial production quarter. Biome was approved for selling cannabis in Saskatchewan, while adding Manitoba to its national supply footprint.